69 citations
,
February 2002 in “International Journal of Cosmetic Science” This review discusses genetic and nutritional causes of hair loss, highlighting that around 90% of treated men show noticeable hair regrowth with a dual inhibitor, while women's hair loss may improve by correcting iron and l-lysine deficiencies.
1 citations
,
May 2017 in “Urologe A” This study reports an increase in the use of tamsulosin/finasteride for benign prostatic syndrome in Germany but highlights that reliable comparisons with monotherapies are lacking due to study design deficiencies.
71 citations
,
November 2012 in “Expert Opinion on Drug Safety” This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.
4 citations
,
June 2015 in “Journal of Genetics/Journal of genetics” This abstract reports funding sources for ongoing research and does not present any study results.
31 citations
,
January 2017 in “Advances in Experimental Medicine and Biology” This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.
14 citations
,
February 2018 in “Psychoneuroendocrinology” This study found that male 5α-reductase 2 knockout mice showed deficits in social dominance behaviors and reduced dopamine receptor binding in a brain region related to social ranking.
February 2021 in “International Journal of Science and Research (IJSR)” This study found that the total testosterone/dihydrotestosterone ratio is significantly higher in women with polycystic ovary syndrome and is associated with a worse metabolic profile in both PCOS and healthy women.
11 citations
,
May 1996 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study reported that 5 alpha-reductase type 2 is the predominant enzyme in pubic skin fibroblasts across normal men, women, and hirsute patients, suggesting potential treatment options for idiopathic hirsutism.
68 citations
,
April 2002 in “Journal of Alternative and Complementary Medicine” This study suggests that botanical 5AR inhibitors like Serenoa repens and β-sitosterol may improve symptoms of androgenetic alopecia, with 60% of treated subjects showing improvement compared to placebo.
65 citations
,
April 2002 in “Journal of Alternative and Complementary Medicine” This study found that 60% of men with mild to moderate androgenetic alopecia showed improvement after treatment with botanically derived 5AR inhibitors, suggesting these compounds may be effective, though larger trials are needed.
52 citations
,
September 2018 in “International Journal of Molecular Sciences” This review highlights the potential of ginseng and its metabolites in preventing hair loss, detailing their hair growth-promoting effects observed in numerous preclinical studies, and emphasizing the underlying mechanisms involved.
25 citations
,
September 1998 in “The Journal of Steroid Biochemistry and Molecular Biology” This study concludes that rhesus macaques are a suitable model for testing the pharmacological properties of finasteride and other 5aR inhibitors, due to their biochemical similarity to humans.
3 citations
,
January 2022 in “Precision medicine and clinical omics” This study reports that using molecular docking methods, beta-sitosterol and stigmasterol from Serenoa repens were identified as potential natural inhibitors of the 5AR1 enzyme, which could serve as novel treatments for androgenetic alopecia based on their inhibitory action observed in a laboratory setting.
3 citations
,
February 2008 in “Basic and clinical dermatology” Telogen Effluvium is a hair loss condition where treatment involves identifying and managing its triggers.
131 citations
,
August 2000 in “International Journal of Dermatology” Inflammation may be linked to hair loss, and targeting specific enzymes could help treat it.
24 citations
,
January 2013 in “Indian Journal of Dermatology, Venereology and Leprology” This review examines hormonal influences on acne development and available hormonal therapies but reports no new clinical results.
6 citations
,
November 2022 in “BMC Urology” In this study, researchers found that the microRNA miR-1199-5p may reduce the expression of SRD5A2 in benign prostatic hyperplasia tissues, potentially contributing to the failure of 5-α reductase inhibitor therapy in some patients.
4 citations
,
August 2021 in “Biomedicine & Pharmacotherapy” This review summarizes the association between 5-alpha reductase inhibitors and depression, discussing potential mechanisms such as neuroactive steroid alterations and neuroinflammation, but reports no new clinical results.
December 2022 in “JAMA network open” This study found that men using 5-alpha-reductase inhibitors showed an increased risk for dementia shortly after starting treatment, which diminished over time, and a consistent association with depression, but no link to suicide.
3 citations
,
October 2019 in “Dermatologic Therapy” This article addresses the mechanisms of androgenic alopecia and seeks to clarify misconceptions, but it reports no new empirical findings and calls for further controlled studies.
2 citations
,
April 2021 in “Canadian Journal of Urology” This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.
62 citations
,
January 2004 in “PubMed” This review describes the shift in treating symptomatic benign prostatic hyperplasia from surgery to 5alpha-reductase inhibitor drugs, which may provide symptom relief and alter BPH's progression, but reports no new clinical results.
November 2023 in “ACS Omega” This study reported that a novel cationic liposome formulation for delivering encapsulated Cas9 protein and sgRNA successfully decreased SRD5α2 mRNA expression by 29.7% in vitro, suggesting a potential alternative treatment option for conditions like prostate cancer and benign prostatic hyperplasia without current drug side effects.
Nutrition plays a key role in managing skin disorders, with specific dietary changes helping improve conditions like acne, dermatitis, psoriasis, alopecia, and skin cancer.
May 2023 in “Scientific Reports” This study found that Lepidium sativum seed extract showed potential in treating alopecia in rats by reducing 5(alpha)-dihydrotestosterone levels and improving hair length compared to minoxidil.
April 2017 in “Austin Journal of Cancer and Clinical Research” This article reviews the role and controversies of 5α-reductase inhibitors like finasteride and dutasteride in managing prostate cancer, without presenting new research results.
122 citations
,
November 2010 in “Journal of Dermatological Science” This study found that increased expression of type II 5α-reductase, androgen receptors, and Hic-5/ARA55 in dermal papilla cells upregulates androgen sensitivity, playing a key role in androgenetic alopecia pathogenesis.
This review suggests that finasteride at 1 mg/day reduces PSA levels similarly to 5 mg/day, but differences in prostate dihydrotestosterone levels may affect prostate cancer diagnosis and prevention.
165 citations
,
December 2002 in “Molecular and Cellular Endocrinology” This study found that finasteride improves scalp hair growth in men with male pattern hair loss by reducing scalp dihydrotestosterone levels, but it did not benefit postmenopausal women with female pattern hair loss.
4 citations
,
November 2022 in “Frontiers in endocrinology” This study found that intracrine androgen signaling via 5α-reductase is essential for optimal endometrial decidualization and vascular development during this process in mice.